The cost effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data

被引：0
|
作者：
Kobelt, G.
Andlin-Sobocki, P.
Collantes-Estevez, E.
Gratacos-Masmitja, J.
Pocovi, A.
Mulero-Mendoza, J.
机构：
[1] European Hlth Econ, Stockholm, Sweden
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Sabadell, Barcelona, Spain
[5] Schering Plough Corp, Madrid, Spain
[6] Clin Puerta Hierro, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：2
相关论文
共 50 条
  • [21] ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS
    Macioch, T.
    Niewada, M.
    Wrona, W.
    Golicki, D.
    Hermanowski, T.
    VALUE IN HEALTH, 2008, 11 (06) : A543 - A543
  • [22] Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Wailoo, Allan
    Bansback, Nick
    Chilcott, Jim
    RHEUMATOLOGY, 2008, 47 (02) : 119 - 120
  • [23] Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice
    Arends, S.
    Brouwer, E.
    Efde, M.
    van der Veer, E.
    Bootsma, H.
    Wink, F.
    Spoorenberg, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : 61 - 68
  • [24] Observation of Clinical Efficacy of Etanercept and Infliximab in Patients with Ankylosing Spondylitis
    Zhang, Fengfei
    Sun, Qingzeng
    Qi, Yudong
    Shen, Yang
    Shi, Yingchun
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 : 426 - 427
  • [25] BASELINE DISEASE PARAMETERS PREDICTIVE OF CLINICAL EFFICACY WITH INFLIXIMAB TREATMENT OF EARLY ANKYLOSING SPONDYLITIS
    Lin, Z.
    Gu, J.
    Liao, Z.
    Ai, M.
    Deng, X.
    Wu, H.
    Cao, S.
    Li, L.
    Wei, Q.
    Wei, Y.
    Tang, D.
    Li, T.
    Pan, Y.
    Wu, Y.
    Xu, M.
    Li, Q.
    Huang, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 622 - 622
  • [26] A COST-EFFECTIVENESS ANALYSIS OF BIOSIMILAR INFLIXIMAB (INFLECTRA®) FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS IN NINE EUROPEAN COUNTRIES
    Rencz, F.
    Brodszky, V
    Pentek, M.
    Gulacsi, L.
    Baji, P.
    VALUE IN HEALTH, 2016, 19 (07) : A540 - A540
  • [27] Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Kobelt, G.
    RHEUMATOLOGY, 2008, 47 (10) : 1589 - 1590
  • [28] Socioeconomic consequences for patients with active ankylosing spondylitis treated for two years with infliximab in a clinical trial
    Brandt, J
    Listing, J
    Krause, A
    Gromnica-Ihle, E
    Kellner, H
    Schneider, M
    Sörensen, H
    Zeidler, H
    Alten, R
    Reddig, J
    Rudwaleit, M
    Sieper, J
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 256 - 257
  • [29] Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
    Fautrel, B.
    Benhamou, M.
    Breban, M.
    Roy, C.
    Lenoir, C.
    Trape, G.
    Baleydier, A.
    Ravaud, P.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (02) : 424 - 427
  • [30] Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation
    de Vries, Mirjam K.
    Wolbink, Gerrit Jan
    Stapel, Steven O.
    de Vrieze, Henk
    van denderen, J. Christiaan
    Dijkmans, Ben A. C.
    Aarden, Lucien A.
    van der Horst-Bruinsma, Irene E.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1252 - 1254
12345